What Happened?

Shares of healthcare diagnostics company QuidelOrtho (NASDAQ: QDEL) jumped 5.5% in the afternoon session after the stock's positive momentum continued as the company highlighted its commitment to transfusion medicine at the Association for the Advancement of Blood & Biotherapies (AABB) 2025 Annual Meeting. 

This move came as the company announced the recent FDA approval of its Micro Typing Systems (MTS) DAT Card. The new product approval expanded QuidelOrtho's portfolio for immunohematology testing. The MTS DAT Card is designed to complete the company's gel-based solution for direct antiglobulin testing. When used with the ORTHO VISION™ Platform, it is intended to help laboratories provide quicker and more dependable results for patients needing timely transfusion decisions. The announcement underscored the company's leadership position in the in vitro diagnostics market.

After the initial pop the shares cooled down to $29.49, up 4.8% from previous close.

Is now the time to buy QuidelOrtho? Access our full analysis report here.

What Is The Market Telling Us

QuidelOrtho’s shares are extremely volatile and have had 35 moves greater than 5% over the last year. In that context, today’s move indicates the market considers this news meaningful but not something that would fundamentally change its perception of the business.

The previous big move we wrote about was 10 days ago when the stock dropped 3.8% as worries over worsening trade relations with China were triggered by critical comments from President Donald Trump. The president's tone and the suggestion of canceling a meeting with President Xi caused a rapid sell-off in the market. The trade dispute flared up after China imposed export controls on rare earth minerals, which are critical components for high-tech manufacturing. The escalation of the trade war raises concerns about supply chain disruptions and increased costs for technology companies, which are heavily reliant on global trade, leading to a broad sell-off in the sector.

QuidelOrtho is down 34.5% since the beginning of the year, and at $29.49 per share, it is trading 38.1% below its 52-week high of $47.61 from January 2025. Investors who bought $1,000 worth of QuidelOrtho’s shares 5 years ago would now be looking at an investment worth $118.19.

Here at StockStory, we certainly understand the potential of thematic investing. Diverse winners from Microsoft (MSFT) to Alphabet (GOOG), Coca-Cola (KO) to Monster Beverage (MNST) could all have been identified as promising growth stories with a megatrend driving the growth. So, in that spirit, we’ve identified a relatively under-the-radar profitable growth stock benefiting from the rise of AI, available to you FREE via this link.